1 to 9 of 10 results

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023


The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Generic Temodar launches in USA


Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages


US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

FDA approves first generic copies of Merck & Co's Singulair; and Pulmicort Respules


The US Food and Drug Administration on Friday approved the first generic versions of Singulair (montelukast…

AstraZenecaGenericsMerck & CoMylan LaboratoriesNorth AmericaPulmicort RespulesRegulationRespiratory and PulmonarySandozSingulairTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Merck & Co prevails in Temodar law suit against Barr/Teva on appeal; Court upholds Shire’s Vyvanse exclusivity


US drug giant Merck & Co (NYSE: MRK) says that a federal appellate court ruled in its favor in a patent…

Barr LaboratoriesLegalMerck & CoNeurologicalOncologyPatentsPharmaceuticalShireTemodarTeva Pharmaceutical IndustriesVyvanse

1 to 9 of 10 results

Back to top